In this episode of The Psychedelic Podcast, Paul F. Austin welcomes back Rick Doblin, Ph.D., Founder and President of MAPS (Multidisciplinary Association for Psychedelic Studies), for a deeply personal and visionary conversation on the recent FDA rejection of MDMA-assisted therapy.
Find full show notes and links here: https://thethirdwave.co/podcast/episode-306/?ref=278
Rick opens up about the painful setbacks, internal missteps, and his own process of recovery and renewed hope. He explains why this isn’t the end—but a critical turning point for psychedelic medicine.
Rick and Paul unpack the nuances of drug plus therapy, exploring why context, integration, and culture matter as much as pharmacology. They reflect on the future of MAPS, the psychedelic renaissance beyond FDA approval, and how business, politics, and spirituality intersect with healing. The episode also explores Rick’s enduring belief in public benefit models, global collaboration, and the potential of a spiritualized humanity.
Rick Doblin, Ph.D., is the Founder and President of MAPS. He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, and has spent nearly four decades advancing the safe and legal use of psychedelics and marijuana through science, education, and advocacy.
Highlights:
- The cost of MAPS' quiet period
- Why MDMA therapy was rejected by FDA
- Pharma vs. therapy: What’s best for patients?
- Drug-only treatments vs. integrated therapy
- Ibogaine’s role in brain healing and PTSD
- MAPS’ path forward: Phase 4 vs. Phase 3
- What the Dutch got right about MDMA
- Spiritualized humanity and self-transcendence
- The global impact of MAPS’ work
- Business, love, and psychedelic ethics
Want to attend this year’s Psychedelic Science 2025 Conference? For our community: Use code THIRDWAVE15 for 15% off registration. Learn more and register at psychedelicscience.org — See you there!
Episode Links
Episode Sponsors:
